Human embryonic stem cell-derived retinal pigment epithelium

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Alimera Sciences and 4 more
3 of 3 findings with company ties

Human trial1

Outcomes

Vision-related quality of life

upin humans1

1 study

Human embryonic stem cell-derived retinal pigment epithelium improves vision-related quality of life in humans (16-25 points in AMD, 8-20 points in Stargardt's).
“Vision-related quality-of-life measures increased for general and peripheral vision, and near and distance activities, improving by 16-25 points 3-12 months after transplantation in patients with atrophic age-related macular degeneration”
Human trialatrophic age-related macular degeneration and Stargardt's macular dystrophysubretinal space3-12 monthsn = 18
Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies
Lancet (London, England)15 Oct 2014

Best-corrected visual acuity

upin humans1

1 study

Human embryonic stem cell-derived retinal pigment epithelium improves best-corrected visual acuity in humans (improved in 10 of 18 eyes).
“Best-corrected visual acuity, monitored as part of the safety protocol, improved in ten eyes, improved or remained the same in seven eyes”
Human trialatrophic age-related macular degeneration and Stargardt's macular dystrophysubretinal spacemedian 22 monthsn = 18
Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies
Lancet (London, England)15 Oct 2014

Serious ocular or systemic safety issues

no changein humans1

1 study

Human embryonic stem cell-derived retinal pigment epithelium has no effect on serious ocular or systemic safety issues in humans.
“There was no evidence of adverse proliferation, rejection, or serious ocular or systemic safety issues related to the transplanted tissue.”
Human trialatrophic age-related macular degeneration and Stargardt's macular dystrophysubretinal spacemedian 22 monthsn = 18
Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies
Lancet (London, England)15 Oct 2014

Latest

Lancet15 Oct